HIV
| 4 min read
FDA rejections and safety concerns, a once-monthly HIV PrEP pill, developments in neuroscience drug development, and more led the news this week.
| 9 min read
Explore how broadly neutralizing antibodies (bNAbs) are offering a new path to an HIV cure by targeting the latent HIV reservoir and preventing transmission.
| 5 min read
What’s stopping major progress in the development of new drugs right now? Biotech leaders and researchers shared their thoughts.
| 4 min read
DDN editors break down a surprising connection between microplastics and antimicrobial resistance, vitamin D for multiple sclerosis, obesity drugs updates, and more news from this week.
| 3 min read
A new vaccination schedule pumps up the immune response to human immunodeficiency virus, overcoming a barrier that has frustrated vaccine designers.
| 10+ min read
Scientists identified specific genes that confer protection or vulnerability to various infections, pointing the way to new treatments.
| 8 min read
Pathogens invade mucosal surfaces like the nose, but typical vaccines don't mount an immune response there. Newly engineered mucosal vaccines, however, do.
| 6 min read
For decades, researchers have tried to craft a successful vaccine for HIV. mRNA vaccines may offer the answer.
| 4 min read
Small molecule drugs that trigger the death of cells storing latent viruses are a promising approach for treating HIV. Researchers identified a potent compound in a marine sponge — a more likely source than it may seem.
| 4 min read
Investigating antibodies produced by infectious diseases yields vaccines with broad-acting protection.
